Effects Of Fibroblast Growth Factor-21Injection On Induced Nonalcoholic Fatty Liver In Vitro

Nonalcoholic fatty liver diseaser (NAFLD) is the manifestation of the metabolie syndrome.Pure fatty liver is formed in the early stage. Fatty hepatitis, hepatic fibrosis, hepatic cirrhosis will be established subsequently. And more and more importance has been attached to the high incidence of fatty liver. Therefore, it is very significant to research and exploitate effectual, cheap, convenient and safety drugs for NAFLD.Objective:To study the effects of fibroblast growth factor-21(FGF21) on induced nonalcoholic fatty liver disease (NAFLD) in vitro and its potential mechanism on the basis of established fatty liver model in vitro.Methods:The HL7702cells were used to do the experimental materials, the nonalcoholic fatty liver model were established by fat emulsion (MFE) in vitro. The concentration of medical fat emulsion was selected by MTT assay. And the cells were divided intio four groups, control groups, MFE induce24h groups, MFE induce48h groups, MFE induce72h groups. The concentration of FGF21was selected by MTT assay, and the FGF21was used to therapy fatty liver model. And the cells was divided intio five groups, model groups, Leaving fat emulsion groups, FGF21therapy6h groups, FGF21therapy12h groups, and FGF21therapy24h groups. Oil red O staining was used to detected lipid droplet under light microscope. The TG levels of intracellulars in each group were observed by hol-automatic biochemistry. An estimation of releasing dose of alanine amino transferase (ALT), aspartate amino transferase (AST) and gamma glutamyl transferases (GGT) in the culture were detected with corresponding bits. Expressions of carnitine palmitovl transferase-1(CPT-1), peroxisome proliferator-activated receptor-gamma (PPARγ) and sterol regulatory element binding protein-1c (SREBP-1c) were determined by immunocytochemistry (ICC). Using x±s to represent experimental data, using SPSS17.0statistical software to analyze the dataa P value of0.01is considered significantly important..Results:The0.1%medical fat emulsion (MFE) was chosen by MTT assay as the best concentration for the induction of nonalcoholic fatty liver, and using MFE induced HL7702cells after48hours, the intracellular TG, ALT, AST and GGT level of nonalcoholic fatty liver cells increased significantly comparing with normal liver cells HL7702(P<0.01), and there was a large quantity of orange-red lipid droplet in cytoplasm of nonalcoholic fatty liver cells, meanwhile, the expression of CPT-1protein got lower and PPARy,SREBP-lc protein got higher. MTT assay showed the best management concentration of FGF21was0.5mg-L-’for setting up the NAFLD-effect model, there was a small quantity of orange-red lipid droplet in cytoplasm of FGF21therapy12h groups cells, the intracellular TG, ALT, AST and GGT levels decreased significantly (P<0.01) in FGF21therapy12h groups, compared with model group, the expression levels of CPT-1protein got higher (P<0.01) and PPARγ, SREBP-lc protein got lower in FGF21therapy12hours groups.Conclusions:We established a cell model of nonalcoholic fatty liver in vitro, FGF21is helpful to relieve accumnlation of TG in NAFLD cells, and it decrease the expressions of PPARγ and SREBP-1c protein,and increase the expressions of CPT-1protein in HL7702cells. And it potential pathogenesis might suppress fat synthesis in cytoplasm by upregulation expression of CPT-1and downregulationexpression of PPARγ and SREBP-1c.